Skip to content
Streamlined path from preclinical to clinical stage

Explore our industry-leading translational models of MASH & MASH-HCC

Gubra’s GAN DIO-MASH model has been top-ranked by LITMUS consortium for its human proximity score and clinical translatability. Explore our entire model portfolio to ensure a successful preclinical study and smooth transition to the clinical stage.

Meet us at EASL 2025

Download Gubra’s EASL Posters


We are attending the EASL Congress from May 7-10, 2025. You can download our posters and explore the clinical translatability of our GAN DIO-MASH model, as well as our other biopsy-confirmed models for MASH and MASH-driven HCC.

Standard Study Outlines

We are experts in bridging preclinical and clinical development.


MICHAEL FEIGH Vice President, Scientific Sales

Michael’s primary focus is on MASH, MASH-HCC, obesity and idiopathic pulmonary fibrosis (IPF). Michael provides customers with scientific expertise in metabolic and fibrotic diseases, and knowhow for the preclinical evaluation of drug candidates from discovery to IND-enabling.

Let’s meet at EASL 2025

Contact us

Gubra

Hørsholm Kongevej 11B 2970 Hørsholm Denmark +45 3152 ­2650

Back To Top